Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide
- 361 Downloads
To determine the risk of severe infection requiring or complicating hospitalization associated with leflunomide therapy in patients with rheumatoid arthritis (RA).
We performed a retrospective study of RA patients who were prescribed leflunomide between 2004 and 2011. Background clinical and laboratory features were compared between patients who suffered severe leflunomide-associated infections and those who did not.
Since January 2005, 401 RA patients have started on leflunomide. Among those, 33 (8.2 %) developed severe infections: pneumonia, oral candidiasis, pyelonephritis, pulmonary tuberculosis, cellulitis, disseminated herpes zoster, tonsillitis, and pulmonary cryptococcosis. Logistic regression showed that age at entry, the presence of DM, and daily dosage of corticosteroid were associated with development of severe infections.
These results showed that some patients with RA who were taking leflunomide developed severe infections requiring hospitalization, and that older age, DM, and a higher daily dosage of corticosteroid were risk factors associated with leflunomide-associated severe infections.
KeywordsInfection Leflunomide Rheumatoid arthritis
Conflict of interest
- 3.Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol. 2004;69:3–8.Google Scholar
- 7.Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353:259–66.PubMedCrossRefGoogle Scholar
- 9.Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, American College of Rheumatology, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.PubMedCrossRefGoogle Scholar
- 10.Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987–94.PubMedCrossRefGoogle Scholar
- 26.Hernández-Cruz B, Sifuentes-Osornio J, Ponce-de-León Rosales S, Ponce-de-León Garduño A, Díaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999;17:289–96.Google Scholar
- 31.Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T, Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1265–8.CrossRefGoogle Scholar